Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12200371 | 0.85 | — | — | |
| SCHEMBL188431 | 0.85 | — | — | |
| SCHEMBL4063270 | 0.75 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL9218081 | 0.74 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL2738575 | 0.74 | — | — | |
| SCHEMBL9745576 | 0.74 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL14360218 | 0.71 | KMT2A (0.40) | SMN1; SMN2MAPT | |
| SCHEMBL13045595 | 0.69 | GABRR1 (0.36) | SMN1; SMN2 | |
| SCHEMBL2806987 | 0.69 | POLB (0.43) | SMN1; SMN2POLBMAPT | |
| SCHEMBL17678526 | 0.68 | IDUA (0.36) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313386-B1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | DSM IP ASSETS BV (NL) | 2012-01-04 | — | — | EP | disclosed |
| US-20110244531-A1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | JLL/DELTA DUTCH NEWCO B.V. (NL) | 2011-10-06 | — | — | US | disclosed |
| EP-2313386-A1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | DSM IP Assets B.V. (NL) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010010165-A1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | DSM IP ASSETS BV (NL) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110244531-A1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | KHK, AGTR2, HK2 | SMN1; SMN2 3290/4885POLB 3341/4885TSHR 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.